Related Experiment Videos
Multiple sclerosis in Jordan: A clinical and epidemiological study.
Khalid El-Salem1, Ehsan Al-Shimmery, Khalid Horany
1Department of Neurosciences, Jordan University of Science and Technology, College of Medicine, King Abdulla University Hospital, PO Box 3030, Irbid 22110, Jordan. khalidelsalem@hotmail.com
Journal of Neurology
|May 2, 2006
Summary
Multiple sclerosis (MS) in Jordan shows a higher prevalence than previously reported, with characteristics similar to global trends. Early onset, relapsing-remitting MS, and interferon use predict better outcomes.
Area of Science:
- Neurology
- Epidemiology
- Clinical Research
Background:
- Multiple sclerosis (MS) is a chronic neurological disease with varying global prevalence.
- Understanding regional epidemiological data is crucial for healthcare planning and resource allocation.
Purpose of the Study:
- To define the clinical, demographic, and epidemiological profile of multiple sclerosis (MS) in Jordan.
- To establish the prevalence of MS in key Jordanian cities.
Main Methods:
- Analysis of data from 224 consecutive Jordanian patients diagnosed with MS between 2004-2005.
- Inclusion criteria followed the McDonald criteria for definite and probable MS.
- Prevalence calculated in Amman and Irbid; disability assessed using the Expanded Disability Status Scale (EDSS).
Main Results:
- A total of 224 patients (87% female) were identified, with a mean age of onset of 29.3 years.
- MS prevalence was 39/100,000 in Amman and 38/100,000 in Irbid.
- Relapsing-remitting MS (90.2%) was the most common pattern; weakness was the most frequent initial symptom.
- Younger age of onset, shorter illness duration, relapsing-remitting course, and interferon use predicted less disability.
Conclusions:
- Jordan is a medium-high risk country for MS, with a higher prevalence than previously documented.
- The findings may indicate an increasing incidence of MS in the region.
- Clinical and demographic features align with international observations.